- Home
- SKYE vs LSAK Comparison
SKYE vs LSAK Comparison
Compare SKYE & LSAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- LSAK
- Stock Information
- Founded
- SKYE 2012
- LSAK 1997
- Country
- SKYE United States
- LSAK South Africa
- Employees
- SKYE N/A
- LSAK N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- LSAK Investment Bankers/Brokers/Service
- Sector
- SKYE Health Care
- LSAK Finance
- Exchange
- SKYE Nasdaq
- LSAK Nasdaq
- Market Cap
- SKYE 108.3M
- LSAK N/A
- IPO Year
- SKYE N/A
- LSAK N/A
- Fundamental
- Price
- SKYE $4.94
- LSAK $5.10
- Analyst Decision
- SKYE Buy
- LSAK
- Analyst Count
- SKYE 6
- LSAK 0
- Target Price
- SKYE $18.67
- LSAK N/A
- AVG Volume (30 Days)
- SKYE 308.0K
- LSAK 18.4K
- Earning Date
- SKYE 11-09-2024
- LSAK 11-06-2024
- Dividend Yield
- SKYE N/A
- LSAK N/A
- EPS Growth
- SKYE N/A
- LSAK N/A
- EPS
- SKYE N/A
- LSAK N/A
- Revenue
- SKYE N/A
- LSAK $564,222,000.00
- Revenue This Year
- SKYE N/A
- LSAK $6.62
- Revenue Next Year
- SKYE N/A
- LSAK $7.87
- P/E Ratio
- SKYE N/A
- LSAK N/A
- Revenue Growth
- SKYE N/A
- LSAK 6.87
- 52 Week Low
- SKYE $1.44
- LSAK $3.00
- 52 Week High
- SKYE $19.41
- LSAK $5.33
- Technical
- Relative Strength Index (RSI)
- SKYE 58.26
- LSAK 58.96
- Support Level
- SKYE $4.01
- LSAK $4.99
- Resistance Level
- SKYE $5.48
- LSAK $5.08
- Average True Range (ATR)
- SKYE 0.46
- LSAK 0.11
- MACD
- SKYE 0.19
- LSAK 0.01
- Stochastic Oscillator
- SKYE 73.79
- LSAK 100.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.